The Insights Association has been racking up advocacy wins for our members in the areas of pharmaceutical research, small business loan forgiveness, telephone research, and jury trial research.
Maine Finalizes Pharmaceutical Regulations, Clarifying the Legality of Research Respondent Incentives for Physicians
In finalizing Maine’s ban on pharmaceutical manufacturer gifts to health care practitioners, the Maine Board of Pharmacy responded to the Insights Association that it should not restrict respondent incentives for participation in bona fide marketing research.
The Insights Association has scored several policy victories in recent months – on Capitol Hill and in states across the U.S. Here are some of the highlights with content links for you and your team, all made possible by your membership.
A look back, counting down the Insights Association's top seven advocacy wins from the last decade that helped our marketing research and data analytics industry members create competitive advantage.
A (data) gathering storm? An update on legislation and regulation impacting the insights industry in 2019
Insights Association lobbyist Howard Fienberg provides a 2019 update on legislation and regulation impacting the marketing research and data analytics industry for Quirks magazine.
Each time the state of Minnesota has tried to clarify treatment of respondent incentives for the participation of health care practitioners in marketing research sponsored by pharmaceutical manufacturers, companies still end up confused. What do the law, regulations and guidance tell us?
As the state legislature considers a bill to prohibit most payments from the pharmaceutical industry to health care providers in connection with their participation in research, a new survey indicates the public health benefits of pharmaceutical marketing research studies of doctors.
Online surveys are the most favored and widely-practiced method to obtain physicians’ opinions about selected pharmaceuticals and related clinical topics.